



WST93AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 09/831,047 Confirmation No.: 8220
Applicant : Blaszczyk-Thurin
Filed : May 3, 2001
TC/A.U. : 1653
Examiner : S. Snedden
Customer No. : 00270
Title : COMPOSITIONS AND METHODS FOR
TREATMENT OF CANCER

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is being filed concurrently with a Request for Continued Examination. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: August 6, 2004
Signature Kelly A. Karstaedt
Name Kelly A. Karstaedt



REMARKS

Listed below is a previously filed and co-pending US Patent application.


- (i) US Patent Application No. 09/894,594, filed June 28, 2001
(US Patent Publication No. US 2003/0017497-A1, published January 23, 2003 - item AF)

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E/Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Application Number	09/831,047
Filing Date	May 3, 2001
First Named Inventor	Blaszczyk-Thurin
Art Unit	1653
Examiner Name	S. Snedden
Attorney Docket Number	WST93AUSA


[illegible][illegible]Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/831,047
				Filing Date	May 3, 2001
				First Named Inventor	Blaszczyk-Thurin
				Group Art Unit	1653
				Examiner Name	S. Snedden
Sheet	2	of	4	Attorney Docket Number	WST93AUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BBZ	BECHTEL et al., "Conformational analysis of the tumor-associated carbohydrate antigen 19-9 and its Lea blood group antigen component as related to the specificity of monoclonal antibody CO19-9", <i>J. Biol. Chem.</i> February 5, 1990 265(4):2028-2037	
	CR	BLASZCZYK et al., "Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related antigens defined by monoclonal antibodies", <i>Cancer Res.</i> January 1984 44(1):245-253	
	CS	BLASZCZYK et al., "Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas", <i>Proc. Natl. Acad. Sci. USA</i> June 1985 82(11):3552-3556	
	CT	BLASZCZYK et al., "Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies", <i>Arch. Biochem. Biophys.</i> August 15, 1984 233(1):161-168	
	CU	BLASZCZYK-THURIN et al., "Biosynthetic pathways for the Leb and Y glycolipids in the gastric carcinoma cell line KATO III as analyzed by a novel assay", <i>Biochem. Biophys. Res. Commun.</i> February 29, 1988 151(1):100-108	
	CV	BLASZCZYK-THURIN et al., "Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy", <i>J. Biol. Chem.</i> January 5, 1987 262(1):372-379	
	CW	FUKUSHI et al., "Location and distribution of difucoganglioside (VI3NeuAcV3III3Fuc2nLc6) in normal and tumor tissues defined by its monoclonal antibody FH6", <i>Cancer Res.</i> August 1985 45(8):3711-3717	
	CX	GENG et al., "Lectin domain peptides from selectins interact with both cell surface ligands and Ca ²⁺ ions", <i>J. Biol. Chem.</i> October 5, 1992 267(28):19846-19853	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Patent Information Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/831,047
				Filing Date	May 3, 2001
				First Named Inventor	Blaszczyk-Thurin
				Group Art Unit	1653
				Examiner Name	S. Snedden
Sheet	3	of	4	Attorney Docket Number	WST93AUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CY	HANSSON et al., "Mouse monoclonal antibodies against human cancer cell lines with specificities for blood group and related antigens. Characterization by antibody binding to glycosphingolipids in a chromatogram binding assay", <i>J. Biol. Chem.</i> April 10, 1983 258(7):4091-4097	
	CZ	HOESS et al., "Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3", <i>Gene</i> June 15, 1993 128(1):43-49	
	CCR	KAUR et al., "Topological analysis of the functional mimicry between a peptide and a carbohydrate moiety", <i>J. Biol. Chem.</i> February 28, 1997 272(9):5539-5543	
	CCS	MAGNANI et al., "A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma", <i>Science</i> April 3, 1981 212(4490):55-56	
	CCT	MARTENS et al., "Peptides which bind to E-selectin and block neutrophil adhesion", <i>J. Biol. Chem.</i> September 8, 1995 270(36):21129-21136	
	CCU	MURALI et al., "Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody", <i>J. Mol. Recog.</i> November-December 1997 10(6):269-276	
	CCV	PASTAN et al., "Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas", <i>Cancer Res.</i> July 15, 1991 51(14):3781-3787	
	CCW	RAO et al., "Sialyl Lewis X mimics derived from a pharmacophore search are selectin inhibitors with anti-inflammatory activity", <i>J. Biol. Chem.</i> August 5, 1994 269(31):19663-19666	
	CCX	RODECK et al., "A mucin containing the X, Y, and H type 2 carbohydrate determinants is shed by carcinoma cells", <i>Hybridoma</i> August 1987 6(4):389-401	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/831,047
				Filing Date	May 3, 2001
				First Named Inventor	Blaszczyk-Thurin
				Group Art Unit	1653
				Examiner Name	S. Snedden
Sheet	4	of	4	Attorney Docket Number	WST93AUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CCY	STAITE et al., "Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin", <i>Blood</i> October 15, 1996 88(8):2973-2979	
	CCZ	STEPLEWSKI et al., "Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants", <i>Proc. Natl. Acad. Sci. USA</i> December 1985 82(24):8653-8657	
	DR	BLASZCZYK-THURIN et al., "Molecular recognition of the Lewis Y antigen by monoclonal antibodies", <i>Protein Eng.</i> May 1996 9(5):447-459	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.